Table 3. Primary Outcomes: Asthma Symptoms, Quality of Life, and Exhaled Nitric Oxide.
| Treatment N=48 Mean (SD) |
Control N=51 Mean (SD) |
95% CI of Beta | *P-value | |
|---|---|---|---|---|
| Symptom Free Days ^ | 11.33 (2.6) | 10.40 (3.4) | −.283, 2.035 | .137 |
| Symptom Days ^ | 1.68 (2.0) | 2.20 (2.2) | −1.374, .261 | .180 |
| Symptom Nights ^ | 1.52 (1.8) | 2.34 (2.2) | −1.675, −.126 | .023 |
| Days of Activity Limitation ^ | 1.21 (1.6) | 2.04 (2.5) | −1.679, −.028 | .043 |
| Days of Rescue Med Use ^ | 1.66 (2.0) | 2.44 (2.6) | −1.950, −.252 | .012 |
| Days Parent Lost Sleep ^ | .59 (1.0) | 1.29 (1.8) | −1.302, −.185 | .010 |
| Days Family Changed Plans ^ | .12 (0.4) | .39 (0.8) | −.542, −.047 | .020 |
| Days Absent from School due to asthma ^ | .37 (0.7) | .85 (1.3) | −.901, −.036 | .034 |
| Quality of Life (range 1-7) | 6.46 (0.7) | 6.31 (0.9) | −.304, .326 | .945 |
| Change in Exhaled Nitric Oxide (ppb) | −9.62 (22.2) | −.39 (14.9) | −17.690, −.773 | .033 |
*
Individual linear regression analyses control for symptoms reported at baseline.
^
Number of days reported over 2 weeks (range 0-14)